Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

35.05 -1.18 (-3.26%)
Streaming Delayed Price Updated: 10:40 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Expert Ratings for Ultragenyx Pharmaceutical ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2023 ↗
 
Via Benzinga
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Where Ultragenyx Pharmaceutical Stands With Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 16, 2023 ↗
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
News headline image
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures ↗
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
News headline image
Ultragenyx to Present at Guggenheim’s Genomic Medicines and Rare Disease Days
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
Dr. Camille Bedrosian to continue employment as strategic development advisor with the company 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Earnings Preview: Ultragenyx Pharmaceutical ↗
 
Via Benzinga
Analyst Expectations for Ultragenyx Pharmaceutical's Future ↗
 
Via Benzinga
News headline image
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Ultragenyx Pharmaceutical ↗
 
Via Benzinga
Analyst Expectations for Ultragenyx Pharmaceutical's Future ↗
 
Via Benzinga
News headline image
Where Ultragenyx Pharmaceutical Stands With Analysts ↗
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter: 
Via Benzinga
News headline image
Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
What You Missed On Wall Street On Friday ↗
In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold. 
Via Talk Markets
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx to Present at Piper Sandler Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Announces Departure of Chief Financial Officer
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx to Present at Upcoming Healthcare Conferences
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 283 companies set new 52-week lows. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 2, 2022 ↗
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.